Akebia Therapeutics (AKBA) Reiterated at Buy by Needham & Company, New Vifor Partnership is a Vote of Confidence Ahead of FDA Decision
Tweet Send to a Friend
Needham & Company analyst Serge Belanger reiterated a Buy rating and $7.00 price target on Akebia Therapeutics (NASDAQ: AKBA) following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
